A5013452356- Contact Dermatitis and Allergies
- Autoimmune Bullous Skin Diseases
- Autoimmune and Inflammatory Disorders
- Soft tissue tumors and treatment
- Dermatology and Skin Diseases
- Pharmaceutical studies and practices
- Genetic and rare skin diseases.
- Acne and Rosacea Treatments and Effects
- Oral Health Pathology and Treatment
- Biosimilars and Bioanalytical Methods
- Colorectal and Anal Carcinomas
- Skin Diseases and Diabetes
- Inflammatory Myopathies and Dermatomyositis
- Advancements in Transdermal Drug Delivery
- Eosinophilic Disorders and Syndromes
- Drug-Induced Adverse Reactions
- Dupuytren's Contracture and Treatments
- Urticaria and Related Conditions
- Parvovirus B19 Infection Studies
- Pharmaceutical Economics and Policy
- Cardiac tumors and thrombi
- Urologic and reproductive health conditions
- Cancer and Skin Lesions
- Dermatological and Skeletal Disorders
- Microscopic Colitis
Hospital Arnau de Vilanova
2018-2025
Hospital de Sagunto
2024
In this original research, we present the results in terms of effectiveness and safety bimekizumab for hidradenitis suppurativa real clinical practice. Results indicated significant improvement all activity scores patient-reported outcomes at week 16, including a notable decrease mean IHS4 from 27.1 to 15.6 (p < 0.001), HS-PGA 5.1 3.2 VAS pain 8.3 4.7 0.001) DLQI 21.6 12.6 0.001). Bimekizumab, administered every 2 or 4 weeks, was well-tolerated with no discontinuations new concerns...
Pilomatrixoma is a benign adnexal tumor very common in pediatric age and young adults that derives from follicular matrix cells. Although clinically it usually presents as subcutaneous nodule of bluish color less than 3cm size, multiple clinicopathological variants have been described the literature. Among these we can find giant pilomatrixoma, rare clinical variant reaches size greater or equal to 4cm simulate presentation malignant neoplasm. We report 59-year-old man with an exophytic...
Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications Network Open Cardiology Health Forum Internal Medicine Neurology Oncology Ophthalmology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy...
We assessed pain, acceptability, patient preference, and tolerability of patients with psoriasis psoriatic arthritis after switching guselkumab from a prefilled syringe to One-Press autoinjector pen. Patients treated for at least 6 months were recruited Jan 2019 Dec 2022. Gender, age, diagnosis, self-administration, pain perception recorded. At the first visit, completed post-auto-injection questionnaire before starting auto-injection pen administration. After 2 self-injection using pen,...
We assessed pain, acceptability, patient preference, and tolerability of patients with psoriasis psoriatic arthritis after switching guselkumab from a prefilled syringe to One-Press autoinjector pen.
Adalimumab (ADA) is a recombinant human monoclonal antibody indicated for the treatment of psoriasis that specifically inhibits tumor necrosis factor. Until recently we only had presentation 40 mg ADA, being standard dose in adults an initial administration 80 mg, followed by every 2 weeks. Newly ADA has been commercialized, allowing or higher dose, with fewer injections. In this study, retrospectively studied 11 patients who have received two dermatology departments hospitals Spain since...